Payment overview · 2025
General Payments
$4,035.39
137 reported records · 26 companies
Healthcare provider profile · identity verified
Afshine A Emrani, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TARZANA, CA · NPI 1356360887
Verified facts
What the public records show
CMS Open Payments records show Afshine A Emrani, MD received $4,035.39 in general payments during 2025 across 137 reported records.
Amgen Inc. accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Entresto, Farxiga, Gemtesa, Horizant, Jardiance, Linzess, Mounjaro, Nexletol, Synthroid, Trelegy Ellipta, Trintellix, Trulance, Ubrelvy, Vraylar, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Viibryd by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 505 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Nexium by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 364 claims for Edarbyclor by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Horizant by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 425 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 557 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 282 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 425 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 413 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $1,077.57 | 26.7% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $794.15 | 19.7% | 26 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $253.22 | 6.3% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $219.85 | 5.5% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $199.31 | 4.9% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $197.57 | 4.9% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $197.26 | 4.9% | 8 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $151.43 | 3.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $130.36 | 3.2% | 5 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $91.89 | 2.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $87.43 | 2.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $86.88 | 2.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.07 | 1.8% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $61.53 | 1.5% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $58.70 | 1.4% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $49.04 | 1.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.98 | 1.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $43.24 | 1.1% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $41.56 | 1.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.28 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $28.67 | 0.7% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.33 | 0.7% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $24.83 | 0.6% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $24.42 | 0.6% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $21.93 | 0.5% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.89 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,035.39 | 137 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $839.48 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $566.08 | 15 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $253.22 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $222.47 | 9 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $219.85 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $199.31 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $197.57 | 9 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $196.64 | 8 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $151.43 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $130.36 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $126.97 | 5 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $91.89 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $87.43 | 3 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $86.88 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $79.99 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $71.07 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $58.70 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.26 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.48 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $49.04 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $45.25 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $43.24 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $43.20 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $41.56 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $38.21 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $31.19 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $28.67 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $28.64 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 69 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 557 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 214 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 236 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| HORIZANT horizant |
2025 | Horizant | 2024 | 55 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 425 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 229 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 194 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 162 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 282 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 189 | exact normalized | Medicare Part D |
| TRULANCE trulance |
2025 | Trulance | 2024 | 90 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 74 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
69 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
229 | 48 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
162 | 36 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
74 | 22 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
505 | 283 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
236 | 61 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
144 | 29 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
364 | 60 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
55 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
425 | 78 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
557 | 94 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
312 | 64 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
282 | 53 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
229 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
425 | 78 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
194 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
214 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
413 | 78 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
90 | 30 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
189 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 1347 | 250 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1079 | 262 |
| Amlodipine Besylate | Amlodipine Besylate | 1034 | 243 |
| Atorvastatin Calcium | Atorvastatin Calcium | 915 | 234 |
| Repatha Sureclick | Evolocumab | 895 | 127 |
| Icosapent Ethyl | Icosapent Ethyl | 886 | 211 |
| Metoprolol Succinate | Metoprolol Succinate | 885 | 216 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 865 | 210 |
| Levothyroxine Sodium | Levothyroxine Sodium | 727 | 162 |
| Metformin Hcl | Metformin Hcl | 638 | 152 |
| Clopidogrel | Clopidogrel Bisulfate | 632 | 128 |
| Escitalopram Oxalate | Escitalopram Oxalate | 620 | 170 |
| Dexlansoprazole Dr | Dexlansoprazole | 602 | 107 |
| Carvedilol | Carvedilol | 562 | 109 |
| Eliquis | Apixaban | 557 | 94 |
| Trazodone Hcl | Trazodone Hcl | 546 | 150 |
| Prolia | Denosumab | 505 | 283 |
| Celecoxib | Celecoxib | 486 | 110 |
| Pitavastatin Calcium | Pitavastatin Calcium | 446 | 97 |
| Jardiance | Empagliflozin | 425 | 78 |
| Nebivolol Hcl | Nebivolol Hcl | 415 | 96 |
| Ozempic | Semaglutide | 413 | 78 |
| Furosemide | Furosemide | 387 | 93 |
| Tamsulosin Hcl | Tamsulosin Hcl | 387 | 81 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 364 | 60 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 358 | 92 |
| Buspirone Hcl | Buspirone Hcl | 350 | 85 |
| Diclofenac Sodium | Diclofenac Sodium | 331 | 68 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 312 | 64 |
| Xarelto | Rivaroxaban | 288 | 62 |
| Doxazosin Mesylate | Doxazosin Mesylate | 284 | 61 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 282 | 53 |
| Mirtazapine | Mirtazapine | 273 | 58 |
| Metformin Hcl Er | Metformin Hcl | 268 | 80 |
| Omeprazole | Omeprazole | 259 | 67 |
| Losartan Potassium | Losartan Potassium | 254 | 66 |
| Prednisone | Prednisone | 244 | 183 |
| Simvastatin | Simvastatin | 241 | 56 |
| Livalo | Pitavastatin Calcium | 240 | 45 |
| Praluent Pen | Alirocumab | 240 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 73 |
| Farxiga | Dapagliflozin Propanediol | 236 | 61 |
| Linzess | Linaclotide | 229 | 48 |
| Montelukast Sodium | Montelukast Sodium | 227 | 45 |
| Entresto | Sacubitril/Valsartan | 214 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 211 | 45 |
| Azithromycin | Azithromycin | 206 | 161 |
| Potassium Chloride | Potassium Chloride | 200 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 199 | 63 |
| Mounjaro | Tirzepatide | 194 | 26 |
| Nifedipine Er | Nifedipine | 194 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 190 | 37 |
| Trintellix | Vortioxetine Hydrobromide | 189 | 37 |
| Lidocaine | Lidocaine | 184 | 40 |
| Tradjenta | Linagliptin | 183 | 31 |
| Gabapentin | Gabapentin | 179 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 165 | 36 |
| Famotidine | Famotidine | 162 | 43 |
| Synthroid | Levothyroxine Sodium | 162 | 36 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 158 | 49 |
| Allopurinol | Allopurinol | 157 | 31 |
| Spironolactone | Spironolactone | 157 | 44 |
| Amiodarone Hcl | Amiodarone Hcl | 154 | 34 |
| Donepezil Hcl | Donepezil Hcl | 153 | 29 |
| Edarbi | Azilsartan Medoxomil | 144 | 29 |
| Febuxostat | Febuxostat | 141 | 33 |
| Bupropion Hcl Sr | Bupropion Hcl | 140 | 44 |
| Ranolazine Er | Ranolazine | 139 | 25 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 131 | 27 |
| Ibandronate Sodium | Ibandronate Sodium | 131 | 40 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 131 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 122 | 105 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 28 |
| Finasteride | Finasteride | 115 | 28 |
| Meloxicam | Meloxicam | 105 | 33 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 102 | 16 |
| Metformin Er Gastric | Metformin Hcl | 100 | 23 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 96 | 17 |
| Sertraline Hcl | Sertraline Hcl | 96 | 23 |
| Ezetimibe | Ezetimibe | 95 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 94 | 20 |
| Myrbetriq | Mirabegron | 93 | 20 |
| Atenolol | Atenolol | 90 | 22 |
| Trulance | Plecanatide | 90 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 39 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 84 | 15 |
| Bystolic | Nebivolol Hcl | 83 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 25 |
| Glimepiride | Glimepiride | 81 | 15 |
| Dexilant | Dexlansoprazole | 78 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 26 |
| Dapagliflozin | Dapagliflozin Propanediol | 74 | 28 |
| Vraylar | Cariprazine Hcl | 74 | 22 |
| Benazepril Hcl | Benazepril Hcl | 70 | 14 |
| Creon | Lipase/Protease/Amylase | 69 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 46 |
| Tadalafil | Tadalafil | 69 | 15 |
| Lisinopril | Lisinopril | 68 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 16 |
| Januvia | Sitagliptin Phosphate | 66 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 64 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 52 |
| Levofloxacin | Levofloxacin | 61 | 54 |
| Lansoprazole | Lansoprazole | 58 | 12 |
| Licart | Diclofenac Epolamine | 58 | 23 |
| Trulicity | Dulaglutide | 58 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 57 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 16 |
| Valsartan | Valsartan | 57 | 20 |
| Bupropion Xl | Bupropion Hcl | 56 | 14 |
| Horizant | Gabapentin Enacarbil | 55 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 54 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 53 | suppressed |
| Clonidine | Clonidine | 52 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 50 | 19 |
| Megestrol Acetate | Megestrol Acetate | 48 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 48 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | 11 |
| Armour Thyroid | Thyroid,pork | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 13 |
| Ibuprofen | Ibuprofen | 43 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 16 |
| Dupixent Pen | Dupilumab | 41 | suppressed |
| Nitroglycerin | Nitroglycerin | 41 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Ketoconazole | Ketoconazole | 39 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Roflumilast | Roflumilast | 37 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Colchicine | Colchicine | 36 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 35 | suppressed |
| Irbesartan | Irbesartan | 34 | 13 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Dutasteride | Dutasteride | 33 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Nexium | Esomeprazole Magnesium | 32 | suppressed |
| Nystatin | Nystatin | 32 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 31 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Dulera | Mometasone/Formoterol | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Folic Acid | Folic Acid | 29 | suppressed |
| Ubrelvy | Ubrogepant | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 27 | suppressed |
| Multaq | Dronedarone Hcl | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Verapamil Sr | Verapamil Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Benicar | Olmesartan Medoxomil | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Nexletol | Bempedoic Acid | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | 17 |
| Aimovig Autoinjector | Erenumab-Aooe | 19 | suppressed |
| Flomax | Tamsulosin Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Cialis | Tadalafil | 17 | suppressed |
| Lipitor | Atorvastatin Calcium | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 12 |
| Uloric | Febuxostat | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Savella | Milnacipran Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Tavaborole | Tavaborole | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lexapro | Escitalopram Oxalate | 13 | suppressed |
| Viibryd | Vilazodone Hcl | 13 | suppressed |
| Avodart | Dutasteride | 12 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Crestor | Rosuvastatin Calcium | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,035.39 · 137 records | Amgen Inc. | ACCRUFER, AIRSUPRA, AMVUTTRA, AZMIRO, Arikayce, BREZTRI, CAMZYOS, CAPLYTA, CREON, DUPIXENT, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, FFRct, FREESTYLE LIBRE 3, GEMTESA, HORIZANT, JARDIANCE, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NP Thyroid 60, REPATHA, SAPIEN 3 Ultra RESILIA, SYNTHROID, TERIPARATIDE, TEZSPIRE, TRELEGY ELLIPTA, TRINTELLIX, TRULANCE, Tymlos, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 30 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error